p.17 抽出テキスト

Israel: Israel Heart Society, Yaakov Henkin; Italy: Italian Federation of Cardiology, Savina Nodari; Kazakhstan: Association of Cardiologists of Kazakhstan, Makhabbat Bekbossynova; Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of Cardiology, Sanda Jegere; Lebanon: Lebanese Society of Cardiology, Samir Arnaout; Libya: Libyan Cardiac Society, Osama Bheleel; Lithuania: Lithuanian Society of Cardiology, Jurgita Plisiene; Luxembourg: Luxembourg Society of Cardiology, Laurent Visser; Malta: Maltese Cardiac Society, Mark Abela; Moldova (Republic of): Moldavian Society of Cardiology, Victoria Ivanov; Montenegro: Montenegro Society of Cardiology, Aneta Boskovic; Morocco: Moroccan Society of Cardiology, Nazzi Mbarek; Netherlands: Netherlands Society of Cardiology, Maarten J.G. Leening; North Macedonia: National Society of Cardiology of North Macedonia, Marijan Bosevski; Norway: Norwegian Society of Cardiology, Elisabeth K. Vesterbekkmo; Poland: Polish Cardiac Society, Jacek Kubica; Portugal: Portuguese Society of Cardiology, Jorge Ferreira; Romania: Romanian Society of Cardiology, Dana Pop; San Marino: San Marino Society of Cardiology, Umberto Maria Stefanelli; Serbia: Cardiology Society of Serbia, Vojislav Giga; Slovakia: Slovak Society of Cardiology, Daniel Pella; Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, Rosa Fernandez-Olmo; Sweden: Swedish Society of Cardiology, Lennart Nilsson; Switzerland: Swiss Society of Cardiology, Isabella Sudano; Syrian Arab Republic: Syrian Cardiovascular Association, Mohamed Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, Faten Triki; Türkiye: Turkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: Ukrainian Association of Cardiology, Olena Mitchenko; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Amitava Banerjee; and Uzbekistan: Association of Cardiologists of Uzbekistan, Aleksandr Shek. ESC Clinical Practice Guidelines (CPG) Committee: Ulf Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski (Poland), and Katja Zeppenfeld (Netherlands). EAS Executive Committee: Børge Grønne Nordestgaard (President) (Denmark), Shoaib Afzal (Denmark), Marianne Benn (Denmark), Kirsten B. Holven (Norway), Meral Kayikcioglu (Türkiye), Ulrich Laufs (Germany), Evangelos Liberopoulos (Greece), Katariina Öörni (Finland), Kausik K. Ray (United Kingdom), and Jeanine Roeters van Lennep (Netherlands).

15 References

1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ ehz455 2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309 3. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/10.1093/ eurheartj/ehab312 4. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388:1353–64. https://doi.org/10.1056/NEJMoa2215024 5. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383: 711–20. https://doi.org/10.1056/NEJMoa2004215 6. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in Familial Chylomicronemia syndrome. N Engl J Med 2019;381:531–42. https://doi.org/10.1056/NEJMoa1715944 7. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 2023; 389:687–99. https://doi.org/10.1056/NEJMoa2304146 8. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of highdose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324: 2268–80. https://doi.org/10.1001/jama.2020.22258 9. Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 2023;330:528–36. https://doi.org/10.1001/jama.2023.11887 10. Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol 2023;81:1–12. https://doi.org/ 10.1016/j.jacc.2022.10.013 11. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. Circulation 2021;143:528–39. https://doi.org/10.1161/CIRCULATIONAHA.120. 052209 12. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus panel. Eur Heart J 2017;38:2459–72. https://doi.org/10.1093/eurheartj/ehx144 13. Cholesterol Treatment Trialists Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5 14. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829–39. https://doi.org/10.1016/S0140- 6736(07)61778-4 15. Mendieta G, Pocock S, Mass V, Moreno A, Owen R, Garcia-Lunar I, et al. Determinants of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll Cardiol 2023;82:2069–83. https://doi.org/10.1016/j.jacc.2023.09.814 16. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/ ehab604 17. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227–337. https://doi.org/10.1093/eurheartj/ehab484 18. van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ, Visseren FLJ, et al. Validation of systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in the EPIC-Norfolk prospective population cohort. Eur J Prev Cardiol 2024;31:182–9. https://doi.org/10.1093/eurjpc/zwad318 19. Fernandez-Friera L, Garcia-Alvarez A, Oliva B, Garcia-Lunar I, Garcia I, Moreno-Arciniegas A, et al. Association between subclinical atherosclerosis burden and unrecognized myocardial infarction detected by cardiac magnetic resonance in middle-aged low-risk adults. Eur Heart J Cardiovasc Imaging 2024;25:968–75. https:// doi.org/10.1093/ehjci/jeae044 20. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;320:281–97. https:// doi.org/10.1001/jama.2018.4242 21. Dzaye O, Razavi AC, Michos ED, Mortensen MB, Dardari ZA, Nasir K, et al. Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial. Atherosclerosis 2022;347:70–6. https://doi.org/10. 1016/j.atherosclerosis.2022.02.006

ESC Guidelines                                                                                                                                                                                          4375

Downloaded from academic.oup.com/eurheartj/article/46/42/4359/8234482 by guest on 07 October 2026